Cyclophosphamide News and Research

RSS

Cyclophosphamide is a drug that is used to treat many types of cancer and is being studied in the treatment of other types of cancer. It is also used to treat some types of kidney disease in children. Cyclophosphamide attaches to DNA in cells and may kill cancer cells. It is a type of alkylating agent. Also called CTX and Cytoxan.

Cyclophosphamide is a synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.

Pigeon virus causes fatal neurological disease in young leukemia patient

A case report details a fatal neurologic disease in an immunocompromised toddler caused by pigeon avian paramyxovirus, underscoring the effectiveness of metagenomic testing in diagnosing complex infectious diseases.

19 Nov 2023

Autologous stem cell transplant shows promise for young patients with severe juvenile systemic sclerosis

New research at ACR Convergence 2023, the American College of Rheumatology's (ACR) annual meeting, shows that patients with refractory juvenile systemic sclerosis improved significantly on nearly all measures for two years following autologous stem cell transplant.

10 Nov 2023

Exploring the link between drugs and microbiota: a growing imperative in precision medicine

The intricate interactions between gut microbiota and drugs.

11 Oct 2023

ACT and personalized cancer vaccine combo shows efficacy in ovarian cancer patients

A Ludwig Cancer Research study has shown that combining adoptive T cell therapy (ACT) with an innovative, personalized cancer vaccine under development at the Lausanne Branch of the Ludwig Institute for Cancer Research can benefit patients with late-stage, drug-resistant ovarian cancer.

21 Sep 2023

Subclonal neoantigens present a key roadblock in MMRd tumor immunotherapy success

Researchers evaluated sensitivity to immune checkpoint blockade (ICB) therapy.

20 Sep 2023

New way to administer CAR-T-cell therapy could lead to fewer side effects

When Richard O'Neil, Ph.D., joined MUSC Hollings Cancer Center two years ago, he knew that he wanted to continue finding ways to make CAR-T-cell therapy easier on patients.

8 Sep 2023

New standard more effective at preventing graft-versus-host disease

Clinicians have a new standard for graft-versus-host disease (GVHD) prevention after allogeneic hematopoietic stem cell transplantation, according to results from a phase III study published June 22 in the New England Journal of Medicine.

22 Jun 2023

Phase I clinical study of TCR NK cell therapy for sarcoma expected to commence later this year

The University of Texas MD Anderson Cancer Center and Replay today announced that the Food & Drug Administration (FDA) has issued a 'safe to proceed' for the Investigational New Drug (IND) application for NY-ESO-1 TCR/IL-15 NK, an engineered T cell receptor natural killer (TCR NK) cell therapy for advanced synovial sarcoma and myxoid/round cell liposarcoma.

20 Jun 2023

First-in-human clinical study begins investigating the duoCAR T-cell therapy for treatment of HIV

UC Davis Health researchers have dosed the second participant in their clinical trial looking to identify a potential cure for HIV utilizing CAR T-cell therapy.

19 Apr 2023

Novel T cell receptor therapy shows early promise for treating solid tumors

Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4), an adoptive T cell receptor (TCR) therapy targeting the MAGE-A4 cancer antigen, achieved clinically significant results for patients with multiple solid tumor types in a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

9 Jan 2023

Exploring remdesivir resistance in COVID-19-infected transplant recipients

In a new study, researchers assessed the remdesivir resistance developed in coronavirus disease 2019 (COVID-19)-infected transplant recipients.

29 Sep 2022

Tumor-infiltrating lymphocytes therapy treats cancers at a large scale

A novel treatment strategy with personalized cell therapy significantly improves progression-free survival compared to standard immunotherapy in patients with advanced melanoma, according to ground-breaking results reported at the ESMO Congress 2022 from the phase 3 M14TIL trial.

12 Sep 2022

Doggybone DNA COVID-19 vaccine can effectively neutralize SARS-CoV-2 variants

Researchers assessed the efficacy of the novel SARS-CoV-2 doggybone deoxyribonucleic acid (DNA) vaccine.

13 Jul 2022

Combination therapy shows promise for treating triple-negative breast cancer

Researchers at Baylor College of Medicine and collaborating institutions have identified a combination therapy for treating triple-negative breast cancer (TNBC) that results in durable tumor regression in an animal model of the condition.

27 Apr 2022

NK cells complexed with bispecific antibody elicit high response rate in patients with resistant lymphomas

Natural killer (NK) cells derived from cord blood that were activated and complexed with a CD30/CD16A bispecific antibody elicited an 89 percent overall response rate in patients with relapsed or refractory CD30+ lymphoma, according to results from a phase I/II clinical trial presented at the AACR Annual Meeting 2022, held April 8-13.

10 Apr 2022

Cyclophosphamide News and Research

Pigeon virus causes fatal neurological disease in young leukemia patient

Autologous stem cell transplant shows promise for young patients with severe juvenile systemic sclerosis

Exploring the link between drugs and microbiota: a growing imperative in precision medicine

ACT and personalized cancer vaccine combo shows efficacy in ovarian cancer patients

Subclonal neoantigens present a key roadblock in MMRd tumor immunotherapy success

New way to administer CAR-T-cell therapy could lead to fewer side effects

New standard more effective at preventing graft-versus-host disease

Phase I clinical study of TCR NK cell therapy for sarcoma expected to commence later this year

First-in-human clinical study begins investigating the duoCAR T-cell therapy for treatment of HIV

Novel T cell receptor therapy shows early promise for treating solid tumors

Exploring remdesivir resistance in COVID-19-infected transplant recipients

Tumor-infiltrating lymphocytes therapy treats cancers at a large scale

Doggybone DNA COVID-19 vaccine can effectively neutralize SARS-CoV-2 variants

Combination therapy shows promise for treating triple-negative breast cancer

NK cells complexed with bispecific antibody elicit high response rate in patients with resistant lymphomas

Neutrophils found to initiate COVID-19-associated olfactory epithelial damage in hamsters

COVID-19 symptoms found to vary in different immune contexts

New drug combination may prevent GvHD after stem cell transplantation for blood cancers

Combination treatment can provide long remissions for young patients with chronic lymphocytic leukemia

Donor cells with clonal hematopoiesis may improve bone marrow transplant outcomes

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News